Blanket Purchase Agreement 36F79720D0136-36E79724A0011
Award Date
3/15/24
Last Date to Order
3/14/26
Federal Agency
National Acquisition Center
Awardee
Ferring Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Department of Veterans Affairs (VA) has awarded Ferring Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer, a multiple-award indefinite-delivery vehicle (IDV) contract against the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), valued at $98.2 million over five years. This contract enables Ferring to supply the oncology medication Adstiladrin (nadofaragene firadenovec) to various Veterans Integrated Service Networks (VISNs) across the United States to support the...
The Department of Veterans Affairs (VA) awarded a Federal Supply Schedule (FSS) contract, valued at up to $3.5 million, to Calliditas Therapeutics US Inc., a foreign-owned, for-profit pharmaceutical company. The contract, under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, facilitates the procurement of TARPEYO, an innovative treatment for uncontrolled protein in urine due to primary immunoglobulin A nephropathy, a serious renal condition impacting some veterans. In addition to the FSS...
The Department of Veterans Affairs (VA) has awarded Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a $3.1 billion multiple-award Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This contract, valid through August 2029, enables the VA and its Veterans Integrated Service Networks (VISNs) to efficiently procure a variety of oncology and specialty medications to support comprehensive healthcare services for veteran patients nationwide. Under...
The U.S. Department of Veterans Affairs (VA) awarded a $3.7 million Blanket Purchase Agreement (BPA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a large pharmaceutical manufacturer. The BPA allows VA medical facilities to place firm fixed price call orders for the oncology medications BALVERSA (erdafitinib) and Belzutifan (WELIREG) through July 2024. This streamlined procurement vehicle supports the VA's Veterans Health Administration (VHA) in maintaining a steady...
The Department of Veterans Affairs (VA) Veterans Health Administration has awarded a Federal Supply Schedule (FSS) contract (36F79723D0079) to Fennec Pharmaceuticals, Inc., a foreign-owned, for-profit pharmaceutical company. This multiple-award contract has a ceiling value of $1,500,000 and a period of performance through February 29, 2028. It covers the provision of drugs, pharmaceuticals, and hematology-related products under FSS Schedule 65 IB, intended to ensure VA medical centers and...
The U.S. Department of Veterans Affairs (VA) awarded Recordati Rare Diseases Inc., a foreign-owned pharmaceutical manufacturer, a $15.6 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.1 million single-award Blanket Purchase Agreement to supply specialized orphan drugs and rare disease treatments. The contract vehicles allow the VA to efficiently procure Recordati's portfolio of medications, including Signifor LAR, Carbaglu, Cystadane, Isturisa, and Cystadrops,...
The Department of Veterans Affairs (VA) has awarded a $19.3 million Federal Supply Schedule (FSS) contract to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide drugs, pharmaceuticals, and hematology-related products under the FSS-61-IB schedule. This multiple-award contract has a period of performance through September 2025. The VA has placed several firm-fixed price delivery orders against this FSS contract for Servier to supply specialty oncology medications such...
The Department of Veterans Affairs (VA) awarded a single-award Blanket Purchase Agreement (BPA) to Recordati Rare Diseases Inc., a division of the Recordati Group, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule. The $3,156,115.00 BPA covers a period of performance from July 2021 to July 2025 and allows the VA to efficiently procure a range of Recordati's specialized orphan drugs, including Signifor, Carbaglu, Cystadane, Isturisa, and Cystadrops. These medications are...
The Department of Veterans Affairs (VA) has awarded Chiesi USA Inc., a foreign-owned for-profit pharmaceutical company, an Indefinite Delivery/Indefinite Quantity (ID/IQ) Federal Supply Schedule (FSS) contract valued at up to $27.7 million for Pharmaceuticals and Drugs (FSS-61-IB). Under this contract, the VA has issued multiple firm fixed price delivery orders to Chiesi USA Inc. for the supply of deferiprone tablets in 1,000 mg doses to VA networks and facilities, including VISN 5, VISN 12, and...
The U.S. Department of Veterans Affairs (VA) awarded a $10 million Blanket Purchase Agreement (BPA) to Servier Pharmaceuticals LLC, a for-profit pharmaceutical company, to provide the specialty oncology medications asparlas and oncaspar over a five-year period. This single-award BPA was issued against Servier's existing Federal Supply Schedule (FSS) contract for pharmaceuticals and drugs. The VA has placed several fixed-price call orders against this BPA for delivery of asparlas and oncaspar...